🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Dr. Reddy's Laboratories Limited DRREDDY NIFTY50NSEAIPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.drreddys.com
Company Profile ↓
₹1,238.70
-1.27% 1Y
Mkt Cap₹1.03 L Cr
P/E24.09
P/B2.73
Div. Yield0.64%
52W High₹1,367.03
52W Low₹1,149.91
Book Value₹451.76
EPS (TTM)₹51.42

Company Overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 11.0% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 24.1, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.21.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹33,593.30 Cr (+3.2% YoY); net profit ₹4,285.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +3.2%, earnings -24.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.0%, profit CAGR -1.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.96%
1 Year:3.19%

Compounded Profit Growth

5 Years:-1.67%
1 Year:-24.22%

Stock Price Performance

1 Year:-1.27%
6 Months:+2.55%
3 Months:+0.88%
1 Month:-2.38%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

AI Exposure AI Pharma / AI in R&D & Manufacturing
Core Focus

Dr Reddy's uses AI in process chemistry, manufacturing optimisation, and biosimilar development. Partnership with Hyderabad-based AI startups for drug repurposing.

Key Initiatives
  • AI in drug discovery & development Dr. Reddy's applies AI/ML to molecule screening, generic-development and bioequivalence workflows to speed time-to-market and improve R&D productivity.
  • AI in manufacturing & quality Machine-learning process control and predictive quality across plants support regulatory compliance and yield in a complex generics operation.
  • Digital therapeutics & commercial AI AI-driven analytics in sales, supply chain and emerging digital-health offerings extend the franchise.
Why Investors Should Care
  • AI is a productivity lever on R&D and manufacturing for a top generics player.
  • Healthy returns (ROCE ~14%) and ~17% five-year profit CAGR with a strong balance sheet.
  • Reasonable P/E ~25 for a defensive pharma compounder.
  • AI benefits are incremental; earnings still hinge on generic pricing and approvals.
AI InvestmentR&D ~9% of revenue.
AI RevenueRevenue ~₹30,000 Cr.
ROI (Now)EBITDA margin ~27%; ROE ~21%.
ROI (Expected)AI-led biosimilars + new launches expected to sustain double-digit growth.

Curated from public filings and analyst commentary; figures are illustrative.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 11.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -1.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
24.09
Industry PE
39.97
Forward P/E
19.46
PEG Ratio
1.57
Book Value
₹451.76
Price to Book
2.73
P/S
3.06
EV/EBITDA
14.98
Dividend Yield
0.64%

Growth (CAGR)

Revenue 5Y
10.96%
Profit 5Y
-1.67%
Revenue (YoY)
3.19%
Earnings (YoY)
-24.22%

Profitability & Returns

ROCE
14.22%
ROE
11.36%
ROA
7.40%
Profit Margin
12.76%
Op Margin
14.92%
Gross Margin
52.77%
EPS (Latest Qtr)
₹2.65
EPS (TTM)
₹51.42

Balance Sheet & Liquidity

Debt/Equity
0.21
Quick Ratio
1.35
Current Ratio
1.80
Debt
₹7,734.10 Cr
Total Assets
₹57,934.60 Cr
Current Assets
₹30,197.50 Cr
Working Capital
₹13,440.90 Cr

Ownership

Promoter Holding
29.77%
Chg in Prom Hold
3.14%
FII / Inst Holding
52.54%
Chg in FII Hold
0.07%

Financial Snapshot

Enterprise Value
₹1.03 L Cr
Total Revenue (TTM)
₹33,593.30 Cr
EBITDA
₹7,916.00 Cr
Free Cash Flow
₹1,833.00 Cr
Operating Cash Flow
₹5,675.50 Cr
Shares Outstanding
₹83.47 Cr
Gross Margin
52.77%
Payout Ratio
15.56%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,238.70 24.09 ₹1.03 L Cr 0.64% 14.22% 11.36% 10.96% -1.67%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 6,315.00 Cr6,758.00 Cr6,903.00 Cr7,237.00 Cr7,114.00 Cr7,696.00 Cr--8,506.00 Cr8,545.20 Cr8,805.10 Cr8,726.80 Cr7,516.20 Cr
Cost of Revenue --------2,850.00 Cr3,682.50 Cr3,991.10 Cr4,046.20 Cr3,212.70 Cr
Gross Profit --------5,656.00 Cr4,862.70 Cr4,814.00 Cr4,680.60 Cr4,303.50 Cr
Operating Expenses 4,781.00 Cr4,696.00 Cr4,894.00 Cr5,214.00 Cr5,283.00 Cr5,566.00 Cr--4,036.00 Cr3,178.50 Cr3,027.30 Cr3,247.60 Cr4,220.60 Cr
Operating Income 1,218.00 Cr1,709.00 Cr1,632.00 Cr1,649.00 Cr1,463.00 Cr1,749.00 Cr--1,620.00 Cr1,684.20 Cr1,786.70 Cr1,433.00 Cr82.90 Cr
EBITDA 1,534.00 Cr2,062.00 Cr2,008.00 Cr2,023.00 Cr1,831.00 Cr2,130.00 Cr--2,526.20 Cr2,464.20 Cr2,430.80 Cr2,158.60 Cr863.00 Cr
Interest Expense 35.00 Cr37.00 Cr35.00 Cr39.00 Cr59.00 Cr60.00 Cr--65.60 Cr83.00 Cr90.70 Cr94.40 Cr105.70 Cr
Pretax Income 1,329.00 Cr1,850.00 Cr1,917.00 Cr1,829.00 Cr1,605.00 Cr1,883.00 Cr--2,005.20 Cr1,904.70 Cr1,835.00 Cr1,542.90 Cr199.70 Cr
Tax Provision 372.12 Cr444.00 Cr440.91 Cr438.96 Cr288.90 Cr489.58 Cr--418.50 Cr495.10 Cr408.20 Cr353.30 Cr-21.60 Cr
Net Income 960.00 Cr1,405.00 Cr1,482.00 Cr1,381.00 Cr1,310.00 Cr1,392.00 Cr--1,593.30 Cr1,417.80 Cr1,437.20 Cr1,209.80 Cr220.90 Cr
Diluted EPS 11.5316.8717.7716.5615.7016.69-16.9419.1017.02-14.522.65

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 15,023.00 Cr15,568.00 Cr14,196.00 Cr14,281.00 Cr15,448.00 Cr17,517.00 Cr19,048.00 Cr-24,587.90 Cr27,916.40 Cr32,553.50 Cr33,593.30 Cr
Cost of Revenue --------10,653.60 Cr11,555.70 Cr13,510.70 Cr15,866.90 Cr
Gross Profit --------13,934.30 Cr16,360.70 Cr19,042.80 Cr17,726.40 Cr
Operating Expenses 11,515.00 Cr11,983.00 Cr11,724.00 Cr11,930.00 Cr12,270.00 Cr15,040.00 Cr15,173.00 Cr-8,028.90 Cr9,829.90 Cr11,841.40 Cr12,714.10 Cr
Operating Income 2,748.00 Cr2,646.00 Cr1,445.00 Cr1,274.00 Cr2,043.00 Cr1,314.00 Cr2,645.00 Cr-5,905.40 Cr6,530.80 Cr7,201.40 Cr5,012.30 Cr
EBITDA 3,508.00 Cr3,585.00 Cr2,472.00 Cr2,351.00 Cr3,178.00 Cr2,477.00 Cr3,874.00 Cr-7,443.10 Cr8,842.20 Cr9,667.10 Cr7,916.00 Cr
Interest Expense 108.00 Cr83.00 Cr63.00 Cr79.00 Cr89.00 Cr98.00 Cr97.00 Cr-142.80 Cr171.10 Cr282.90 Cr373.80 Cr
Pretax Income 2,900.00 Cr2,859.00 Cr1,554.00 Cr1,350.00 Cr2,336.00 Cr1,886.00 Cr2,884.00 Cr-6,036.70 Cr7,187.00 Cr7,678.40 Cr5,481.70 Cr
Tax Provision 551.00 Cr743.34 Cr295.26 Cr432.00 Cr397.12 Cr-132.02 Cr922.88 Cr-1,530.00 Cr1,618.60 Cr1,953.90 Cr1,235.10 Cr
Net Income 2,336.00 Cr2,131.00 Cr1,292.00 Cr947.00 Cr1,950.00 Cr2,026.00 Cr1,952.00 Cr-4,506.70 Cr5,568.40 Cr5,654.40 Cr4,285.00 Cr
Diluted EPS 27.4324.9815.5911.4123.4924.3823.47-54.1866.9267.7951.42

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 18,457.00 Cr20,330.00 Cr21,654.00 Cr22,349.00 Cr22,418.00 Cr23,223.00 Cr26,588.00 Cr-32,185.40 Cr38,751.80 Cr49,298.90 Cr57,934.60 Cr
Current Assets --------20,425.30 Cr24,804.90 Cr25,011.20 Cr30,197.50 Cr
Cash & Equivalents --------577.90 Cr710.70 Cr1,465.40 Cr1,536.80 Cr
Inventory --------4,867.00 Cr6,355.20 Cr7,108.50 Cr7,653.10 Cr
Receivables --------7,248.50 Cr8,029.80 Cr9,042.00 Cr10,121.90 Cr
Total Liabilities --------9,086.30 Cr10,696.80 Cr15,582.30 Cr19,888.90 Cr
Current Liabilities --------8,584.50 Cr9,603.90 Cr13,039.20 Cr16,756.60 Cr
Long Term Debt -------380.00 Cr-380.00 Cr380.00 Cr1,220.30 Cr
Total Debt 4,314.00 Cr3,352.00 Cr4,918.00 Cr5,071.00 Cr3,838.00 Cr2,210.00 Cr3,031.00 Cr-1,347.20 Cr2,002.00 Cr4,676.60 Cr7,734.10 Cr
Total Equity 9,853.00 Cr12,569.00 Cr12,262.00 Cr12,572.00 Cr14,024.00 Cr15,599.00 Cr17,641.00 Cr-23,099.10 Cr28,055.00 Cr33,338.80 Cr37,706.30 Cr
Shares Outstanding --------83.26 Cr83.41 Cr83.45 Cr83.47 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 2,524.00 Cr3,263.00 Cr2,144.00 Cr1,803.00 Cr2,870.00 Cr2,984.00 Cr3,570.00 Cr-5,887.50 Cr4,543.30 Cr4,642.80 Cr5,675.50 Cr
Investing Cash Flow -2,370.00 Cr-1,610.00 Cr-1,890.00 Cr-1,483.00 Cr-769.00 Cr-495.00 Cr-2,255.00 Cr--4,137.30 Cr-4,028.30 Cr-5,807.70 Cr-6,551.30 Cr
Financing Cash Flow -433.00 Cr-1,700.00 Cr-369.00 Cr-444.00 Cr-2,133.00 Cr-2,516.00 Cr-30.00 Cr--2,686.10 Cr-376.30 Cr1,891.10 Cr829.00 Cr
Capital Expenditure -1,515.00 Cr-1,198.00 Cr-1,218.00 Cr-1,090.00 Cr-622.00 Cr-572.00 Cr-1,247.00 Cr--1,886.60 Cr-2,743.50 Cr-3,439.80 Cr-3,842.50 Cr
Free Cash Flow 1,009.00 Cr2,065.00 Cr926.00 Cr713.00 Cr2,248.00 Cr2,412.00 Cr2,323.00 Cr-4,000.90 Cr1,799.80 Cr1,203.00 Cr1,833.00 Cr
Net Change in Cash -280.00 Cr-47.00 Cr-114.00 Cr-124.00 Cr-31.00 Cr-27.00 Cr1,286.00 Cr--935.90 Cr138.70 Cr726.20 Cr-46.80 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------56.7%58.6%58.5%52.8%
Operating Margin % 18.3%17.0%10.2%8.9%13.2%7.5%13.9%-24.0%23.4%22.1%14.9%
Net Margin % 15.5%13.7%9.1%6.6%12.6%11.6%10.2%-18.3%19.9%17.4%12.8%
ROE % 23.7%17.0%10.5%7.5%13.9%13.0%11.1%-19.5%19.8%17.0%11.4%
ROCE % --------25.0%22.4%19.9%12.2%

Shareholding Pattern

Insiders
29.77%
Institutions
52.54%
Public Float
74.80%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DRREDDY

Google News hu, 09 Jul 2026

Why is Dr Reddy’s Laboratories stock sliding today? - Investing.com

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQLWZ5bGQzOEUteDh4WlROREJQeV81MHQzeXFEZXF6eml4NXh3ZVZHNjUtZXZJYU04WDRVcDRiMC1SM3VzMEFfandIaWZXOTl3dzNxcGROVFBhdmRKSllfZ2VsLVg5ZFBIZ0o4WEhyaS1GblpqY1d5TU1lWWpwNUk0azNxd3NaRnh2WnlrOG…

Google News hu, 09 Jul 2026

Dr Reddy's Shares Slide Over 6% After Semaglutide Batch Quality Concern - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQTUNvWUs3TDV5c0Z5cHN5MUtUWTdOeEg1Sk0tbGRJR1RzSXhNeXZmTG5Uc2tyWXNleksxN3dUeVhVS0NKUGJGelNLWER5c3RPSzNFUFZLOUFqVENyWWtGbTZ6VFNSYUxVbUJkdWVGRnBJeHZ5YWswN1hmdl9xc1hjX0prX01zcVZCU3BvMk…

Google News Mon, 22 Jun 2026

Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.7% and Still Underv - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNeEhpdHpIeWVNcHJoUUlDOHdOeDI3dnRRcVh3M2o0X2FuQjNaNEgyUHVxTlpMUEp5SkE3eFJhVGZoUWNFZHdJTDRNcVNLcVdGN2lsaEVzMFExc3U3bTFSWHdkbWFKdkFrU21JNkpTLTg5SnpLTDhuOVFTZzFtUnlNRlNERkpiVkxTbVlkTE…

Google News ue, 07 Jul 2026

Is It Smart To Buy Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Before It Goes Ex-Dividend? - webull.com

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1DZkgzYUh4amRUNTlncHpySHktVWFjV29yRDV2M1RoalpjNGRlVk5LZVIybGZmQnU5WHlieGV2blBDaU1WX0QyaE9oSTZKckl2eG9wYVdoX3I?oc=5" target="_blank">Is It Smart To Buy Dr. Reddy's Laboratories Limi…

Google News hu, 09 Jul 2026

Dr Reddy’s Shares Sink 6% on Semaglutide Supply Delay - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQYVhJWDAwVVlqTWZMSEZpU0FqZTgxWUpXU3JVVm0yWDBUMzROenJ6NmdSZU1mN0ZTZ2xtbmdyWkRNclJNZ1V2Q0hUWUs2OHd3VFM4aHE4am5FdmlrT3hQZHNKQUh4Z0VpU3RuUFdudTNMRXBvWG5EcFB1NTlMTWdSVDBpeGtRc3pB?oc=5"…

Google News Fri, 10 Jul 2026

DRREDDY Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE56cHQwQUhablB6YXRqeHVPanN2QndQZ0ZiSWh4ajNRZVVqWlVzVEtqWUN4S29Ka3ZyYXpWYUV1UmFVb0paX2dWalFacTFfSXBFMkUteEVfdWhqQkQ3T1RCU1hKQWtpN3FzMFE?oc=5" target="_blank">DRREDDY Outlook for the …

DRREDDY — Frequently Asked Questions

What is the current share price of Dr. Reddy's Laboratories Limited (DRREDDY)?

As of 2026-07-15 09:52 IST, Dr. Reddy's Laboratories Limited (DRREDDY) trades at ₹1,238.70 on NSE. Its 52-week range is ₹1,149.91 to ₹1,367.03.

What is the market capitalisation of DRREDDY?

Dr. Reddy's Laboratories Limited (DRREDDY) has a market capitalisation of ₹1.03 L Cr on NSE.

What is the P/E ratio of DRREDDY?

DRREDDY trades at a trailing price-to-earnings (P/E) ratio of 24.09. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.73.

Does DRREDDY pay a dividend?

Dr. Reddy's Laboratories Limited (DRREDDY) currently offers a dividend yield of 0.64%.

What is the return on equity (ROE) of DRREDDY?

DRREDDY has a return on equity (ROE) of 11.36%. Its return on capital employed (ROCE) is 14.22%.

Is DRREDDY a good stock to buy?

This page provides a data-driven analysis of Dr. Reddy's Laboratories Limited (DRREDDY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space